Quick Read
-
Medtronic yields 3.11% at a forward P/E of 15, beating Abbott’s 2.4% yield and forward P/E of 17 on both income and value.
-
Abbott’s 203% ten-year return dwarfs Medtronic’s 40%, making it the stronger pick for retirees still in accumulation mode with a long horizon.
-
Medtronic’s five-quarter EPS beat streak is the critical risk to watch, given that a guidance miss on FY27 would erase its yield advantage over Abbott.
-
Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Abbott Laboratories didn’t make the cut. Enter your email to see the names that beat ABT. The report is free. Enter your email and see if any of your stocks made the cut.
For a retirement investor deciding between Medtronic (NYSE:MDT) and Abbott Laboratories (NYSE:ABT) today, the question is blunt: which medical device dividend deserves the retirement dollar right now? One pays more today. The other has raised longer and compounded harder. That is the trade, and it deserves a direct answer rather than a split decision.
Dimension 1: The Dividend Itself
Medtronic yields 3.11% on a forward annualized payout of $2.88, backed by 49 consecutive years of dividend increases and a most recent bump from $0.71 to $0.72 quarterly. Abbott yields 2.4% on $2.52 annualized, but carries 54 consecutive years of increases as an S&P 500 Dividend Aristocrat, with a fresher lift from $0.59 to $0.63.
Medtronic generated $7.33 billion in operating cash flow in FY26 against a $3.64 billion dividend payout. Abbott returned $2.1 billion to shareholders in Q2 2026 alone via dividends and buybacks. Abbott has the longer streak and the faster recent raise (the kind of 50-plus-year runway that put it in our free Dividend Kings guide, where we ranked ten of them by today’s valuation). Medtronic delivers materially more income per dollar invested today. Winner for income now: Medtronic.
Free Report, Just Released
Why Didn’t ABT Make The Top 10 List?
24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.
And ABT didn’t make the cut!
The report is free, and you can see why we think each stock is a top investment today.
Enter Your Email and See the Ten →
Dimension 2: The Underlying Business
Abbott is the broader franchise: medical devices, diagnostics (now supercharged by the $21 billion Exact Sciences acquisition completed March 23, 2026), established pharmaceuticals, and nutrition. Diversification cushions any one reimbursement or regulatory shock. Q2 2026 revenue reached $12.59 billion (+13.02% YoY), with medical devices up 9.0% and continuous glucose monitors clearing $2 billion in quarterly sales.
